H2020HORIZONFP7
Cliniques Universitaires Saint-Luc Asbl
- Country
- BEBelgium
- Defence projects
- 0
- Projects, all programmes
- 21
- As coordinator
- 0
- EU contribution (CORDIS)
- EUR 4,613,676
- Active
- 2009 to 2025
Projects
21 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| EUmetriosisEUmetriosis: Transforming endometriosis care in Europe: an integrated approach to enhance understanding, diagnosis, tailored management and patient empowerment | HORIZON | 2025 | Third party | Not stated |
| MDR-RADefining Clinical and Molecular Phenotypes of Multi-Drug Resistance in difficult to treat Rheumatoid Arthritis | HORIZON | 2025 | Participant | EUR 213,000 |
| ARTEMISAcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients | HORIZON | 2024 | Participant | EUR 296,500 |
| e-QuoLe-health tools to promote Equality in Quality of Life for childhood to young adulthood cancer patients, survivors and their families - a PanEuropean project supported by PanCare and Harmonic consortia | HORIZON | 2024 | Participant | EUR 158,875 |
| HT-ADVANCEImproving treatment efficacy in hypertension by biomarker-guided personalised decision support | HORIZON | 2023 | Participant | EUR 353,750 |
| TIGERProof of Principle of the best-in-class therapeutic mRNA cancer vaccine | H2020 | 2021 | Participant | EUR 311,435 |
| QSPainReliefEffective combinational treatment of chronic pain in individual patients, by an innovative quantitative systems pharmacology pain relief approach. | H2020 | 2020 | Participant | EUR 67,500 |
| V.A. CureA multidisciplinary approach towards sustainable improvement in rare diseases care uniting Europe's top class vascular research to find new treatment strategies for vascular anomalies | H2020 | 2019 | Partner | EUR 0 |
| 3TRIdentification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions | H2020 | 2019 | Participant | EUR 434,093 |
| IMMUcanIntegrated IMMUnoprofiling of large adaptive CANcer patients cohorts | H2020 | 2019 | Participant | EUR 30,000 |
| IMI-PainCareImproving the care of patients suffering from acute or chronic pain | H2020 | 2018 | Participant | EUR 134,044 |
| IMMUNOSABRClinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer | H2020 | 2017 | Participant | EUR 115,175 |
| ChiLTERNChildren’s Liver Tumour European Research Network | H2020 | 2016 | Participant | EUR 236,402 |
| Microbes4UStudy of the therapeutic potential of an Akkermansia muciniphila-based products in subjects with an increased cardio-metabolic risk. | H2020 | 2016 | Third party | Not stated |
| SPCCTIn Vivo Spectral Photon Counting CT Molecular Imaging in Cardio- and Neuro-Vascular Diseases | H2020 | 2016 | Participant | EUR 96,721 |
| SEPCELLTitle of Proposal: Restoring the immune system homeostasis and organ function in severe community acquired pneumonia- induced sepsis through adipose derived allogeneic stem cells (SEPCELL Proje | H2020 | 2015 | Participant | EUR 534,375 |
| OPERAMOPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly | H2020 | 2015 | Third party | Not stated |
| BETA3_LVHA multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease | H2020 | 2015 | Third party | Not stated |
| COMBACTE-MAGNETCombatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections | FP7 | 2015 | Participant | EUR 663,000 |
| COMBACTE-NETCombatting Bacterial Resistance in Europe | FP7 | 2013 | Participant | EUR 719,243 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.